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Abstract
Long non-coding RNA (lncRNA) may contribute to the initiation and progression of tumor. In this 
study, we first systematically compared lncRNA and mRNA expression between GBM and paired 
normal brain tissues using microarray data. We found 27 lncRNA and 82 mRNA significantly up-
regulated in GBM, as well as 198 lncRNA and 285 mRNA significantly down-regulated in GBM. 
We identified 138 co-expressed lncRNA-mRNA pairs from these differentially expressed lncRNA 
and genes. Subsequent pathway analysis of the lncRNA-paired genes indicated that EphrinB-
EPHB, p75-mediated signaling, TNF alpha/NF-κB, and ErbB2/ErbB3 signaling pathways might 
be altered in GBM. Specifically, lncRNA RAMP2-AS1 had significant decrease of expression in 
GBM tissues and showed co-expressional relationship with NOTCH3, an important tumor 
promoter in many neoplastic diseases. Our follow up experiment indicated that (1) an 
overexpression of RAMP2-AS1 reduced GBM cell proliferation in vitro and also reduced GBM 
xenograft tumors in vivo; (2) NOTCH3 and RAMP2-AS1 co-expression rescued the inhibitory 
action of RAMP2-AS1 in glioblastoma cells; and (3) RNA pull-down assay revealed a direct 
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interaction of RAMP2-AS1 with DHC10, which may consequently inhibit, as we hypothesize, the 
expression of NOTCH3 and its downstream signaling molecule HES1 in GBM. Taken together, 
our data revealed that lncRNA expression profile in GBM tissue was significantly altered; and 
RAMP2-AS1 might play a tumor suppressive role in GBM through an indirect inhibition of 
NOTCH3. Our results provided some insights into understanding the key roles of lncRNA-mRNA 
co-regulation in human GBM and the mechanisms responsible for GBM progression and 
pathogenesis.
Keywords
Glioblastoma; Glioma stem cells; LncRNA-mRNA co-expression network; lncRNA-RAMP2-
AS1; NOTCH3
Introduction
Gliomas account for approximately 30% of primary tumors in the brain (1), and can be 
categorized into four grades (I-IV) by the histopathological classification according to The 
World Health Organization (WHO) (2). Among the four grades, glioblastoma (GBM, grade 
IV) has the most dismal prognosis with an overall survival of less than 14 months (1). 
Despite multimodal and aggressive treatments that include surgical resection, local 
radiotherapy and systemic chemotherapy, the outcome of GBM patients remains poor (3, 4). 
To improve treatment efficacy, a better understanding of glioma pathogenesis at the genetic 
and molecular levels is urgently needed.
Molecular profiling of normal and tumor tissues has revealed that long non-coding RNA 
(lncRNA) is dysregulated in many human malignancies, including prostate (5), colorectal 
(6), breast (7), bladder (8), liver (9) and brain cancers (10). Multiple lncRNA genes are 
postulated to function as oncogenes and tumor suppressors and regulate many hallmarks of 
cancer. In particular, the regulatory roles of lncRNA in expression, activity and localization 
of protein-coding genes have attracted much attention (11).
Recent evidence has indicated that lncRNA may play important roles in glioma pathogenesis 
(12, 13). For example, it has been reported that lncRNA may regulate biological processes in 
glioma, such as cellular proliferation and apoptosis, which contribute to tumorigenesis (14). 
Aberrant expression of lncRNA has also been implicated for clinical phenotypes (15) and 
patient prognosis of GBM (16), which could be further exploited as potential diagnostic and 
therapeutic targets (17).
An increasing number of lncRNAs have been characterized in cancer including GBM, 
lncRNA H19 has been shown to promote glioma angiogenesis and invasion (18, 19). 
Another study reported that knockdown of lncRNA XIST exerted tumor-suppressive 
functions in human glioblastoma stem cells by up-regulating the microRNA -152 (20). 
lncRNA HOTAIR was found to be a cell cycle-regulator and essential for proliferation in 
human glioblastoma (21, 22). Although these lncRNAs were found their roles in some 
glioma paradigm, systematic investigation of lncRNA in GBM has not been reported yet 
(23). In this study, we performed a systematic analysis of lncRNAs with their paired mRNAs 
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in GBM, from which the we pinpointed several lncRNAs whose aberrant expression in 
GBM specimens potentially altered GBM-specific pathways. Specifically, we studied the 
function of a lncRNA, RAMP2-AS1, in GBM both in vitro and in vivo. Our data indicated 
that RAMP2-AS1 might contribute to GBM through targeting the NOTCH3 signaling 
pathway. Our study provides some important insights of lncRNAs into the mechanisms 
responsible for GBM pathogenesis.
Materials and Methods
Acquisition of clinical specimens and ethical standards
Glioblastoma specimens were obtained from 20 GBM patients who underwent surgical 
treatment at Navy General Hospital, China, from January 2011 to December 2013 (Table 
S1). Glioma was diagnosed according to the 2007 WHO Classification of Tumors of the 
Central Nervous System. Normal samples were obtained from the normal brain tissues 
around the tumors (approximately 2-3 cm from the tumor border) of the same GBM patients. 
Written informed consent of the patients was provided by their legal surrogates to permit 
surgical procedures and use of resected tissues. This study was approved by the Specialty 
Committee on Ethics of Biomedicine Research, Navy General Hospital of PLA, China 
(permission number: 0506-2006).
Microarray expression profiles for lncRNA and mRNA
The Agilent human lncRNA and mRNA array V4.0 was designed with four identical arrays 
per slide (4 × 180K format), with each array containing probes interrogating approximately 
41,000 and 34,000 human lncRNAs and mRNAs, respectively. These lncRNA and mRNA 
target sequences were merged from multiple databases, such as 23,898 from GENCODE 
(V19) (24), 14,353 from Human LincRNA Catalog (25), 7760 from RefSeq, 5627 from 
UCSC (http://genome.ucsc.edu/), 13,701 from NRED (ncRNA Expression Database, http://
nred.matticklab.com/cgi-bin/ncrnadb.pl), 21,488 from LNCipedia (http://
www.lncipedia.org/), 1038 from H-InvDB (http://www.h-invitational.jp/hinv/ahg-db/
news.jsp), 3019 from lncRNAs-a (Enhancer-like) (25), 1053 from Antisense ncRNA 
pipeline (26), 407 Hox ncRNAs, 962 UCRs (27), and 848 from Chen Ruisheng lab (Institute 
of Biophysics, Chinese Academy of Science, http://www.ibp.cas.cn/nRNA). Each RNA 
sequence was detected by probes and repeated twice. The array also contained 4974 control 
probes from Agilent. Data normalization of the 2 channel ratios was achieved using an 
intensity-dependent “Lowess” module implemented in the R programming language. 
Differential expression (DE) of lncRNA/gene was defined according to the following 
criteria: > 2.0 fold-change and P <0.05. We have submitted the data of microArray to GEO. 
The GEO accession number is GSE77452 (Differentially expressed lncRNAs and genes in 
GBM compared to matched normal brain samples).
RNA extraction, labeling and hybridization
Total RNA was extracted from 3 pairs of snap-frozen GBM specimens and matched 
noncancerous tissues using Trizol (Invitrogen, California), and purified with mirVana 
miRNA Isolation Kit (Ambion, Austin, TX, USA) according to manufacturer's protocol. The 
amplified cRNA was purified using the RNA Clean-up Kit (MN). The cDNA, labeled with a 
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fluorescent dye (Cy5 and Cy3-dCTP), was produced by Eberwine's linear RNA 
amplification method and subsequent enzymatic reaction. Labeled controls and test samples, 
labeled with Cy5-dCTP and Cy3-dCTP, were dissolved in 80 μL hybridization solution 
containing 3×SSC, 0.2% SDS, 5×Denhardt's solution and 25% formamide. Arrays 
hybridization was performed in an Agilent Hybridization Oven overnight at a rotation speed 
of 20 rpm and a temperature of 42°C, then washed with two consecutive solutions (0.2% 
SDS and 2× SSC) at 42°C and room temperature for 5 minutes.
lncRNA-gene co-expression network construction
Pre-processed RNA-Seq data of 19 different human normal tissues including brain was 
downloaded from lncRNA function database (28). The downloaded expression profiling data 
consisted of 13,249 lncRNA and 20,447 protein-coding genes. We excluded lncRNA or 
genes that had low variance (belonged to lowest quartile). Furthermore, an lncRNA or 
mRNA gene was excluded from the analysis if >25% samples had missing values. We 
computed Pearson correlation coefficient for all possible lncRNA-gene, lncRNA-lncRNA, 
and gene-gene pairs. A pair was considered as significantly co-expressed if the absolute 
correlation score was >0.75 and correlation P<0.05 (P values adjusted by Benjamini-
Hochberg multiple test correction method) (29).
Quantitative real-time polymerase chain reaction (qRT-PCR) validation
Total RNA was extracted from 3 GBM and 3 matched normal brain samples using TRIzol 
reagent (Invitrogen Life Technologies), and then reverse-transcribed using Fermentas RT 
reagent Kit (Perfect Real Time) according to the manufacturer's instructions. Two 
microgram of total RNA was converted to cDNA according to the manufacturer's protocol. 
Expression of lncRNA was measured by real-time RT-PCR using SYBR Premix Ex Taq on 
MX3000 instrument. The primers used in this study are shown in Table S2. PCR was 
performed in a total reaction volume of 8 μl, including 5 μl 2×PCR master mix (Superarray), 
0.5 μl of PCR Forward Primer (10μM), 2 μl of cDNA, and diluted to 8 μl with double 
distilled water. The quantitative real-time RT-PCR reaction was set at an initial denaturation 
step of 10 minutes at 95°C; and 95°C (10 seconds), 60°C (60 seconds), 95°C (10 seconds) in 
a total 40 cycles, with a final step heating slowly from 60 to 99°C. All samples normalized 
to GAPDH to calculate relative lncRNA concentrations.
Cell lines and cell culture
The human glioblastoma cell lines U87 and U251 were obtained from the American Type 
Culture Collection. These cell lines were purchased between 2006 and 2010 and 
authenticated by morphologic and growth curve analysis before this study beginning. U87 
and U251 cell lines were derived from human glioblastoma specimens and cultured in 
D/F12 medium supplemented with 10% fetal bovine serum (FBS), (Hyclone, USA).
Lentiviral infection and gene transfection
Lentivirus (LV) containing RAMP2-AS1 (P34516) and NOTCH3 full-length sequence were 
obtained from Shanghai GenePharma Co., Ltd. Viral particles were harvested 48 hours after 
cotransfection of the lentiviral vector (or the control LV vector) and the packaging vectors 
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into HEK293T cells using Lipofectamine 2000 (Life Technologies Corporation, Carlsbad, 
CA, USA). U87 and U251 cells were then infected with the LV (LV-RAMP2-AS1 or LV-
NOTCH3), or the control virus (NC). The infection ratio was determined by fluorescence 
labeling and real-time RT-PCR.
Cell cycle distribution
U87 and U251 cells (1×105 cells) were plated in 60-mm culture plates, and the cells were 
infected with LV-RAMP2-AS1, LV- NOTCH3 and control virus respectively. After 96h, the 
cells were trpsinized, fixed in 70% ethanol, washed once with PBS, and then labeled with 
propidium iodide (Sigma-Aldrich, USA) in the presence of RNase A (Sigma-Aldrich) for 30 
min in the dark (50g/mL). Samples were run on a FACScan flow cytometer (Becton-
Dickinson, USA), and the percentages of cells within each phase of the cell cycle were 
analyzed using Cell Quest software.
Cell proliferation analysis
Glioblastoma cells (2×103 cells per well) were placed into 96-well plates. Cells were 
infected with LV-RAMP2-AS1 and LV controls for 24, 48 and 72 hours, respectively. 
Thereafter, CCK-8 reagent was added to the cells. The cells were further cultured for two 
hours, and the optical density (OD) at 450 nm was measured by a microplate reader 
according to the manufacturer's instructions (Thermo Fisher Scientific, USA).
Immunofluorescent staining
Cells were washed three times with ice-cold PBS and fixed with 4% paraformaldehyde-PBS. 
Cell were then incubated with 0.1% Triton-PBS for 15 minutes, 1% bovine serum albumin-
PBS for 10 minutes, and then treated with goat anti-human Ki67 monoclonal antibody 
(1:1000, Santa Cruze, Texas, USA at 4°C overnight. FITC labeled mouse anti-goat IgG 
(1:1000, Santa Cruz, Texas, USA) was used for visualization.
RNA pull-down assay
Biotin-labeled RNAs were in vitro transcribed using the Biotin RNA Labeling Mix and T7 
RNA polymerase (Ambion, USA), and purified with the RNeasy Mini Kit (QIAGEN, 
Germany) on-column digestion of DNA. To prepare the glioblastoma cell-U87 nuclear 
extract, frozen U87 cells were homogenized using a dounce homogenizer with 15-20 strokes 
in nuclear isolation buffer (250 mM sucrose, 10mM Tris-HCL [PH 7.5], 1mM EDTA with 
protease inhibitors). Nuclear pellets were collected by centrifugation at 1,000 × g for 10 min, 
resuspended in 1 ml RNA immunoprecipitation buffer (150mM Nacl, 20 mM Tris[PH7.4], 
1mM EDTA, 0.5% Triton X-100 with protease inhibitors and RNaseOUT). The lysates were 
mechanically sheared again using a dounce homogenizer with 15–20 strokes. Nuclear 
membrane and other debris were pelleted by centrifugation at 12,000 rpm for 10 min. The 
folded sense or anti-sense RNAs (1 ug) were added into 2 mg pre-cleared nuclear lysates 
(supplemented with 0.2 mg/ml heparin, 0.2 mg/ml yeast tRNA and 1 mM DTT) and 
incubated at 4_C for 1 hr. Sixty microliters of washed Streptavidin-coupled Dynabeads 
(Invitrogen, USA) were added to each binding reaction and further incubated at 4°C for 1 hr. 
Beads were washed briefly five times with RIP buffer and heated at 70°C for 10 min in 13 
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LDS loading buffer, and the retrieved proteins were visualized by SDS-PAGE and silver 
staining. The unique protein bands shown in the sense RNA pull-down were identified by 
Mass Spectrometry.
Western blot
Protein lysates were prepared as previously described (30). The protein samples were 
resolved by SDS-PAGE and transferred onto PVDF membranes (Roche, Basel, 
Switzerland). The membranes were then incubated with the following antibodies: Rabbit 
anti-NOTCH3 (Cell Signaling Technology, USA), mouse anti-HES1 (R&D, USA), mouse 
anti-DHC10 (R&D, USA) and mouse anti-P16/P21/P27 (Santa Cruz, USA). 
Chemiluminescence antibody-labeled protein bands were detected using a G:BOX F3 
(Syngene, Cambridge, UK).
Xenografts
U87 and U251 (3×108 cells) infected with LV-RAMP2-AS1 or LV control were injected 
(subcutaneous) into the upper right flanks of nude mice. Thirty days after injection, the 
xenograft were harvested and volumes measured according to the formula: V (mm3) = (a)×
(b2/2), where a is the largest diameter of tumor and b is the smallest diameter of tumor. For 
conducting intracerebral xenografted tumors, nude mice were anesthetized and 
stereotaxically inoculated in the right striatum (Bregmaanteroposterior: −0.5mm, 
mediolateral: +2mm, dorsoventral: −3mm) with 1×108 tumor cells derived from the 
subcutaneous tumors. After 3 weeks of intracerebral implantation, the mice were 
anesthetized deeply and perfused with saline that contained 100 U/ml of heparin (Sigma-
Aldrich, USA). They were then fixed with 4% of poly-formaldehyde that was prepared in 
PBS. Next, the paraffin sections (4μm) of the xenografted tumors were analyzed by H&E 
staining. Experiments involving mice were performed in accordance with an approved 
Institutional Animal Care and Use Committee protocol (permission number: 0308-2013).
Statistical analysis
The difference in results between two groups was examined by two-tailed Student t-test, a P 
value <0.05 was considered statistically significant. The mean ± S.D. values were displayed 
in the figures. All statistical analyses were performed and graphs were generated using the 
SPSS software (version 12.0; Windows platform), or R software package (version 3.2.2). 
Detail survival analysis using a cohort of 20 GBM patient samples (in-house data) or 150 
GBM patient samples (extracted from The Cancer Genome Atlas [TCGA] project) was 
provided in Supplemental data 1.
Results
Systematic identification of lncRNA in GBM
We first performed microarray expression profiling of lncRNA and mRNA in 3 human GBM 
and matched normal brain tissue samples. These analyses yielded 27 up- and 198 down-
regulated lncRNA, as well as 82 up- and 285 down-regulated protein-coding genes in GBM 
compared to normal brain tissues of the same patients that passed the criteria of >2 fold-
change and P <0.05 (Fig. 1A). Next, we mapped the aberrantly expressed lncRNA and 
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mRNA onto an lncRNA-mRNA co-expression network, which was constructed based on 
significant expression correlation (absolute Pearson correlation coefficient >0.75, P <0.05 
after adjusted by Benjamini-Hochberg [BH] multiple testing correction method) (31) among 
all the lncRNA and protein-coding genes across 19 human normal tissues, including brain 
(32). In the network, there were three types of co-expression links: between a coding RNA 
and a coding RNA, between a non-coding RNA and a coding RNA, and between a non-
coding RNA and a non-coding RNA (Fig. 1B). For each type of co-expression link, we 
summarized dysregulation patterns of associated molecules, number of dysregulated links, 
lncRNA, and genes in Supplemental Table S3 (33).
To illustrate functional importance of the dysregulated lncRNA, we performed pathway and 
Gene Ontology (GO) term enrichment analyses of their co-expressed genes that were also 
differentially expressed in GBM. This approach facilitated prioritizing lncRNA whose 
aberrant expression potentially alters the expression of genes that belong to GBM specific 
pathways and biological processes (BPs). We identified 10 significantly enriched pathways 
(adjusted P <0.05, hypergeometric test followed by BH multiple test correction) using the 
Pathway Commons database as the pathway annotation dataset (34), which is embedded into 
the software WebGestalt (28, 35) (Supplementary Table S4). Intriguingly, most of the 
inferred pathways are linked to functions related to GBM pathogenesis, such as EphrinB-
EPHB pathway, p75(NTR)-mediated signaling, TNF alpha/NF-kB, Neurotrophic factor-
mediated Trk receptor signaling, and ErbB2/ErbB3 signaling events (Fig. 1C). The GO 
functional annotations were also informative in the context of GBM development. 
Specifically, we obtained 11 BP terms (non-redundant terms that belong to level 5 or more), 
among which most are closely linked to the biology of neurogenesis, neuron regeneration 
and differentiation. The result suggested that these relevant biological functions might be 
altered in the origin and development of GBM (Supplementary Table S5).
From the GBM relevant pathways and GO BP terms, we pinpointed 4 protein-coding genes 
and their co-expressed lncRNAs (ENSG00000197291-NOTCH3, ENSG00000226645-
ARHGAP32, ENSG00000261684-NKIRAS1, and ENSG00000234741-SRC) 
(Supplemental Table S6) and performed real-time RT-PCR using 3 pairs of snap-frozen 
GBM specimens and matched noncancerous tissues to verify whether these important 
pathway-linked molecules were indeed dysregulated in GBM. Our real-time RT-PCR 
confirmed aberrant expression patterns of all the lncRNA (except ENSG00000226645) and 
genes that were observed in the microarray data (Fig. 2), suggesting that these lncRNAs and 
genes were dysregulated in GBM patient samples and that they might have important roles 
in GBM pathology. For example, in the co-expression network, lncRNA 
ENSG00000197291 (RAMP2-AS1) was linked to NOTCH3, a key regulator of many 
signaling pathways involved in cancer stem cells (CSCs) differentiation and development of 
glioma (36-39). It has been shown that activation of NOTCH3 promotes invasive glioma in a 
tissue-specific manner (40). The results from both the microarray and real-time RT-PCR 
showed that, when compared with normal brain tissue, the expression level of RAMP2-AS1 
in GBM significantly decreased (P<0.05), whereas the expression of NOTCH3 significantly 
increased (P<0.05, Fig. 2).
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Low RAMP2-AS1 expression correlates with poor prognosis in GBM
Considering the lower expression of RAMP2-AS1 in GBM than normal brain tissue, we 
further examined whether RAMP2-AS1 expression correlated with patient survival. We 
separated 20 GBM patient samples into two groups by using the median expression of 
RAMP2-AS1. Our analysis revealed that the patients with low expression of RAMP2-AS1 
had significantly shorter survival times (P <0.001, log-rank test; Fig. 3A) than those with a 
high expression level of RAMP2-AS1 (detail procedure in Supplementary data1). We also 
assessed 5-year survival by dividing a larger cohort of 150 GBM patients extracted from 
TCGA project into two groups based on the median RAMP2-AS1 expression 
(Supplementary data1). The result showed a similar trend to what we observed in our patient 
samples, though statistical significance is moderate (P =0.094, log-rank test; Fig. 3B).
RAMP2-AS1 regulates the cell cycle progression mediated by NOTCH3
To determine the exact effects of RAMP2-AS1 on the growth of GBM cells, we generated 
GBM cell lines with over-expression of RAMP2-AS1 by infection with the LV-RAMP2-
AS1. The immunofluorescence and qRT-PCR analysis showed that the infection efficiency 
of LV-RAMP2-AS1 in U251 and U87 were greater than 90% (Figs. 4A and 4B). U87 and 
U251 cells were infected with LV-RAMP2-AS1 only, or co-infected with LV-NOTCH3 at 
the same time. At 96h after treatment, flow cytometry was performed to examine the cell 
cycle. We found that RAMP2-AS1 overexpression could block the GBM cell cycle progress 
and NOTCH3 co-expression rescued the cell cycle arrest (Fig.5A). The proteins which are 
relative to cell cycle, such as P21, P27 and P16 were prepared for Western blot analysis. The 
result showed that RAMP2-AS1 overexpression decreased the expression of P21 
significantly and NOTCH3 could restore P21 to basal levels (Fig.5D).
RAMP2-AS1 inhibits GBM cell growth
Cell-counting kit-8 assays indicated that cell proliferation was reduced in both U87 and 
U251 cells when RAMP2-AS1 was over-expressed (P<0.05, Fig. 5B). Consistent with the 
decrease in cell proliferation, we observed a significant lower level of Ki67 expression 
(0.2808±0.091 and 0.3911±0.185236) in U87 and U251 cells, which had increased RAMP2-
AS1 expression, than that of the control cells (0.59189±0.1734 and 0.5282±0.2050) (P<0.05, 
Fig. 5C).
To further evaluate the effects of RAMP2-AS1 on GBM growth in vivo, RAMP2-AS1-
overexpressing U87 and U251 cells and the negative control cells (those were infected with 
control virus) were injected into the flanks of nude mice. Tumors were allowed to grow for 
30 days and then they were extracted and measured for mean volumes. The xenografts of 
U87 and U251 cells with overexpressed RAMP2-AS1(269±80.56mm3 and 403±62.17mm3) 
were significantly smaller than those GBM tumors formed from control cells 
(1355±76.32mm3 and 1447±85.95mm3) (P <0.05, Figure 6A, 6B). Furthermore, the H&E 
staining of intracranial implanted tumors showed that the subcutaneous tumors still 
remained the pathologic characters of GBM, such as cellular heterogeneity, rapid 
proliferation, angiogenesis and extensive invasion (Figure 6 A). The results above indicated 
that RAMP2-AS1 inhibited the growth of GBM cells both in vitro and in vivo, suggesting its 
tumor suppressive role in GBM.
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RAMP2-AS1 may regulate the proliferation of GBM through NOTCH3 signaling
Our co-expression network analysis suggested that RAMP2-AS1 expression correlated with 
NOTCH3 expression (Fig. 1). To determine whether NOTCH3 is regulated by RAMP2-AS1, 
we measured the expression of NOTCH3 after over-expression of RAMP2-AS1. Expression 
of NOTCH3 protein and its downstream signaling molecule, HES1, decreased significantly 
in both U87 and U251 cells which were infected by LV-RAMP2-AS1 when we compared 
with those cells expressing control vector (P= 0.039738, Fig. 5D). To determine the 
specificity of NOTCH3 regulation, we overexpressed NOTCH3 together with RAMP2-AS1 
in U87 and U251 cells, and did not observe the reduction of HES1 expression by Western 
blot analysis (Fig. 5D). Furthermore, we observed that the growth inhibition of U87 and 
U251, both in vitro and in vivo induced by RAMP2-AS1 over-expression, was rescued by 
NOTCH3 over-expression (Fig. 5B, Fig.5C and Fig. 6). These results suggested that the 
RAMP2-AS1-mediated down-regulation of NOTCH3 likely contributed to the reduction of 
GBM proliferation.
RAMP2-AS1 interacts with DHC10 to regulate NOTCH3 expression
We next investigated how RAMP2-AS1 regulates NOTCH3 expression. First, we performed 
an RNA pull-down experiment using nuclear extracts of U87 cells to identify the proteins 
interacting with RAMP2-AS1. Several additional bands were present in the SDS-PAGE 
silver staining analysis of the fraction precipitated with biotin-labeled RAMP2-AS1 
compared to an antisense control (Fig. 7A). Proteins in these specific bands were identified 
by mass spectrometry, one of which was human dynein heavy chain 10 (DHC10), a known 
microtubule-associated protein (41). We confirmed the specific interaction between DHC10 
and RAMP2-AS1 by immunoblotting (Fig. 7B). Next, qRT-PCR confirmed that 
DNAH10siRNA in combination with RAMP2-AS1 could restore NOTCH3 expression 
associated with RAMP2-AS1 depletion (Fig. 7C). Put together, our data suggested that 
RAMP2-AS1 might inhibit the expression of NOTCH3 mediated by DNAH10 in GBM 
pathology.
Discussion
GBM is the most common and aggressive type of primary brain tumor in humans. It 
accounts for 52% of all parenchymal brain tumor cases and 20% of all intracranial tumors 
(42). Although the mechanisms of GBM occurrence and development have been extensively 
investigated during the past two decades, the pathogenesis of this disease is still ill defined, 
and the gene regulation involved in this disease remains largely unclear.
Increasing lines of evidence suggested that lncRNA may be important factors in controlling 
gene expression (43). Hence, we examined the expression profiles of both lncRNAs and 
mRNAs in GBM tissue and matched control samples (Fig.1A). Subsequently, we 
constructed lncRNA-mRNA co-expression network based on publicly available, matched 
lncRNA and mRNA expression profiling data and mapped the differently expressed 
lncRNAs and mRNAs in GBM into this unique reference network. This approach was taken 
to examine which lncRNA-mRNA pairs have been aberrantly expressed in GBM and have 
potential roles in the origination and development of GBM. Our results may better reflect 
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the genetic variations of GBM due to the ruling out the difference at the individual level. 
Thus, this co-expression network analysis could generate useful hypotheses for further study 
of the functional roles of the differentially expressed lncRNAs in the development of GBM. 
Importantly, our systems biology approach found that the abnormally expressed lncRNAs 
were mostly involved in the pathways and biological functions that are related to GBM 
pathogenesis, indicating the effectiveness of our approach.
While the functional roles of most of the lncRNAs in the co-expression network have not 
been previously studied, the mRNAs that have co-expression relationship with those 
lncRNAs have been previously reported to have important roles in various tumors including 
prostate cancer, glioma, breast cancer and squamous cell carcinoma of the lung (39, 44-45). 
Therefore, according to the functional roles of these mRNAs, we could prioritize the 
lncRNAs that might play key roles in GBM. Our investigation of lncRNA-mRNA network 
revealed that NOTCH3, a key gene in the progression of GBM, had co-expression 
relationship with the lncRNA RAMP2-AS1. The expression of RAMP2-AS1 was 
significantly reduced in GBM. Notch signaling has a critical function in the specification, 
proliferation, and survival of stem/progenitor cells in a number of tissues, including the 
central and peripheral nervous systems (46). The pathway is widely implicated in neoplasia, 
and in most contexts it promotes neoplastic growth (47-52). It has been shown that activation 
of NOTCH3 pathway promotes murine T-acute lymphoblastic leukemia (T-All), similar to 
that has been seen in humans (50, 53, 54).
Notch is also thought to play important role in poorly differentiated tumor cells. Inhibition 
of this pathway may deplete “cancer stem cells”, which are resistant to radiation and 
standard chemotherapies (55-58). Small molecules targeting Notch have shown great 
promise in preclinical testing of several tumor models. Based on such studies, phase I 
clinical trials for leukemia and breast cancer have been initiated using gamma-secretase 
inhibitors that block the activation of Notch receptors (59, 60). Similar to leukemia and 
breast, Notch signaling pathway has also been shown to promote proliferation of glioma 
cells and play different roles in primary and secondary GBM (61, 62); however, the 
mechanisms of Notch regulation in GBM has not yet clear.
In our study, we found that RAMP2-AS1 expression was significantly reduced in primary 
GBM tissues compared with normal brain tissues and lower RAMP2-AS1 expression was 
correlated with poor overall survival of GBM patients (Fig. 3). We utilized a cohort of 150 
GBM patient samples from TCGA and a cohort of 20 patient samples from our in house 
data. Although the survival analysis of a large cohort of 150 GBM patients extracted from 
TCGA showed that the patients with low expression of RAMP2-AS1 had only moderately 
shorter survival times than those with a high expression level of RAMP2-AS1 (P =0.094, 
log-rank test; Fig. 3B, Supplementary data 1), the survival analysis of our in-house 20 
primary GBM revealed significant survival difference between the two groups. Several 
factors might contribute to the difference between the two datasets: specimens background 
(ethnic background, gender, age, etc.), sample heterogeneity and treatment (e.g., all the 20 
in-house GBM samples were primary GBM and the patients had experienced the same 
treatment), and statistical power.
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Recently, Pastori et al. applied single molecule sequencing to quantify the expression of 
lncRNAs in GBM. They reported the top 100 up- and down- regulated lncRNAs in GBM 
versus control samples, and RAMP2-AS1 was not found in that list (63). Pastori et al. used 
epilepsy samples as control, while we used matched normal brain tissue samples. This 
different selection of control tissues may partially explain why RAMP2-AS1 showed 
different result in the two studies, though further investigation is warranted. Our co-
expression network analysis of lncRNA-mRNA genes revealed that RAMP2-AS1 was 
significantly correlated with NOTCH3, which was significantly up-regulated in GBM (Fig.
2). This is consistent with many previous studies in which Notch signaling acts as a tumor 
promotor (45, 46). Our study also showed that over-expression of RAMP2-AS1 inhibited the 
proliferation of GBM cells in vitro and in vivo in part by down-regulating NOTCH3 and its 
downstream molecule, HES1(Fig.5, Fig.6). These results indicated that RAMP2-AS1 might 
contribute to GBM through its regulation of NOTCH3. Furthermore, although we did not 
detect the direct interaction between RAMP2-AS1 and NOTCH3, our RNA pull-down 
experiment indicated another protein, DHC10 had direct interaction with RAMP2-AS1. For 
all the results we had, we speculated that RAMP2-AS1 might interact with NOTCH3 
mediated by DHC10 (Fig.7).
While our results are still preliminary, the findings are promising toward setting us future 
research direction focusing on lncRNA-mRNA synergistic regulation in the pathogenesis of 
GBM. It is our belief that the lncRNA-mRNA pairs highlighted in EphrinB-EPHB, p75-
mediated signaling, TNF alpha/NF-κB and ErbB2/ErbB3 signaling pathways warrant future 
investigation in GBM or its related phenotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flowchart for deciphering functional lncRNA(s) in GBM. The framework has the following 
major steps. A, Identification of differentially expressed (DE) lncRNAs and genes in GBM 
compared to matched normal samples. Volcano plots show DE probes for lncRNAs and 
mRNA genes. X-axis and Y-axis show fold-change and −log(P values), respectively. Red, 
green, and grey dots represent up-, down-, and no significant expression change, 
respectively. B, Construction of lncRNA-gene co-expression network. Red and green circle 
nodes denote up- and down-regulated genes, respectively. Red and green v-shaped nodes 
denote up- and down-regulated lncRNAs, respectively. Up- or down-regulation was 
measured in GBM patient samples compared to the matched normal brain tissues. Edges 
denote significant expression correlation between nodes. C, Detection of GBM-specific 
pathways and Gene Ontology biological process terms enriched in lncRNA-gene co-
expression network. D, Selection of lncRNAs and genes of interest to perform follow-up 
experiments in-vitro and in-vivo to determine lncRNA's pathogenic potential in GBM. 
Additionally, Kaplan-Meier analysis assessed the ability of the selected lncRNA to predict 
survival of GBM patients using an in-house as well as a large cohort of GBM patient 
samples available in The Cancer Genome Atlas (TCGA) project.
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Figure 2. 
Real-time RT-PCR verification of lncRNA and mRNA expression. Four lncRNAs and four 
mRNAs were selected to examine their expression between GBM and normal control by 
real-time RT-PCR.
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Figure 3. 
Decreased expression of RAMP2-AS1 in GBM correlates with poor clinical outcome of 
GBM patients. A, Kaplan-Meier survival curves using the data from 20 GBM patients with 
respect to RAMP2-AS1 expression. B, A large cohort of 150 GBM patient samples from 
TCGA was evaluated by Kaplan-Meier analysis with respect to RAMP2-AS1 expression.
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Figure4. 
The infection effect of LV-RAMP2-AS1 on GBM cells. A, After 96h of LV-RAMP2-
AS1(5×108TU/ml) infection, U87 and U251 cells were observed under fluorescence 
microscope. B, After 96h of LV-RAMP2-AS1 infection, qRT-PCR were performed to 
analyze the expression of RAMP2-AS1in U87 and U251 cells. Experiments were performed 
in triplicate in three times. The values shown are mean ± SD. *P <0.05 vs. control group.
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Figure 5. 
RAMP2-AS1 inhibits the growth of GBM cells. A, Flow cytometry was performed to 
examine the S arrest in U87 and U251 cells after treatment with control LV vector LV-NC, 
LV-RAMP2-AS1(RAMP2-AS1) and LV- NOTCH3 combined with LV-RAMP2-AS1 
(Notch3+RAMP2-AS1) for 96h. B, U87 and U251 GBM cells which were infected with 
above vectors respectively and subjected to CCK-8 cell proliferation assays. C, Ki67 
expression of U87 and U251 GBM cells which were infected with above vectors 
respectively were detected by immunofluorescence (left). The Ki67 data is presented as the 
ratio of Ki67 positive cells (light blue) to total DAPI positive cells (light blue U dark blue) 
(right). D, The expression of protein NOTCH3, HES-1 and P21 in U87 and U251 cells was 
determined by Western blot after 72h of above vectors infection. All above experiments 
were performed in triplicate in three times. The values shown are mean ± SD (n=5 in each 
group). *P <0.05 vs. control group.
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Figure 6. 
RAMP2-AS1 inhibits the growth of GBM in vivo. A, U87 and U251 GBM cells which were 
infected with LV-NC, LV-RAMP2-AS1 and LV- NOTCH3 combined with LV-RAMP2-AS1 
were injected subcutaneously into nude mice. After 30 days tumors were removed and 
photographed and their volumes were measured. There were five mice in each group. *: P 
<0.05 each group vs. the NC group (right). The tumor cells derived from above 
subcutaneous xenografts were implanted into right striatum of nudes and analyzed by H&E 
staining (left). B, The volume of subcutaneous xenografts of the groups mentioned above. 
Bars are mean±SD. *p<0.05, n=5 per group.
Liu et al. Page 20
Mol Cancer Ther. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure7. 
RAMP2-AS1 interacts with DHC10. A, Silver-stained SDS-PAGE gel analysis of proteins in 
nuclear extract of U87 cells that are bound to biotinylated RAMP2-AS1 or its antisense. The 
highlighted regions were analyzed by mass spectrometry, identifying DHC10 as a protein 
unique to RAMP2-AS1 (left). Immunoblotting analysis of proteins in nuclear extract of U87 
cells that are bound to biotinylated RAMP2-AS1 or its antisense using an anti-DHC10 
antibody (right). B, NOTCH3 expression in U87 cells receiving LV, LV-RAMP2-AS1, 
scramble siRNA(scrb si), or DHC10siRNA in combination as indicated (Error bars represent 
SD, *p<0.05).
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